Plasmid DNA from AGC is already supplied as a starting material for the companies' COVID-19 vaccine
Biopharma CDMO AGC Biologics will supply more plasmid DNA starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
Pfizer and BioNTech have started to develop a vaccine for the Omicron variant of COVID-19, with first batches expected to be ready for delivery by end of March 2022.
“We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants,” said AGC Biologics CEO, Patricio Massera. “Our pDNA services are a part of our growing global Cell and Gene Therapy offering that includes the development and manufacturing of cell therapies, viral vectors, and messenger RNA.”
“This type of work is what drives us every day,” said AGC Biologics General Manager, Heidelberg, Dieter Kramer. “We appreciate this opportunity to help make a difference in the lives of people around the world and produce life-saving treatments.”